SMaRT for Therapeutic Purposes

Area of Science:

• Molecular Biology
• Gene Therapy
• RNA Splicing

Background:

• Spliceosome-mediated mRNA trans-splicing (SMaRT) is an emerging therapeutic strategy for genetic diseases.
• SMaRT involves correcting target pre-mRNAs using exogenous pre-mRNA trans-splicing molecules (PTMs).
• Optimizing the ratio of trans-splicing to cis-splicing is critical for therapeutic efficacy.

Purpose of the Study:

• To provide guidelines for designing effective PTMs for SMaRT.
• To develop a rapid screening assay for evaluating PTM efficiency.
• To assess the therapeutic potential of optimized PTMs in a native-like setting.

Main Methods:

• Development of guidelines for PTM design.
• Establishment of a high-throughput screening assay to measure trans-splicing efficiency.
• Testing of selected PTMs using mini-gene assays to evaluate performance in a more native context.

Main Results:

• The study outlines a protocol for designing PTMs.
• A fast screening assay was developed to assess PTM efficiency.
• Selected PTMs were further validated using mini genes to assess therapeutic potential.

Conclusions:

• Effective PTM design and efficient screening are crucial for advancing SMaRT therapies.
• The developed protocol and assay facilitate the identification of promising PTM candidates.
• Further validation in native settings is essential for clinical translation of SMaRT.